

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

Aloxi (palonosetron)

CG-DRUG-33

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Aloxi (palonosetron)

APPROVAL CRITERIA

Requests for Aloxi (palonosetron) may be approved for adults as prevention of any of the following:

- I. Acute or delayed nausea and vomiting associated with initial and repeat courses of moderately or highly emetogenic cancer chemotherapy; **OR**
- II. Postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

Requests for Aloxi (palonosetron) may be approved for an infant, child, or adolescent (age 1 month to less than 17 years) as prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.

Aloxi (palonosetron) may **not** be approved for all other uses.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Aloxi [Product Information]. Albuquerque, NM. OSO Biopharmaceuticals; December 2015. Available at: <http://www.aloxi.com/docs/pdf/PI.pdf>. Accessed on June 15, 2018.
2. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetic use in oncology: updated guideline recommendations from ASCO. Am Soc Clin Oncol Educ Book. 2012:532-540.
3. Hesketh PJ, Kris MG, Basch, E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice update. J Clin Oncol. 2017; 35(28):3240-3261.
4. National Comprehensive Cancer Network®. NCCN Antiemesis Guidelines. V3.2018. For additional information visit the NCCN website: <http://www.nccn.org>. Accessed on June 15, 2018.
5. National Comprehensive Cancer Network®. NCCN Drugs & Biologic Compendium™ (electronic version). For additional information visit the NCCN website: <http://www.nccn.org>. Accessed on June 15, 2018.
6. Palonosetron HCl. In: DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated June 8, 2018. Available at: <http://www.micromedexsolutions.com>. Accessed on June 15, 2018.
7. Palonosetron HCL Monograph. Lexicomp® Online, American Hospital Formulary Service® (AHFS®) Online, Hudson, Ohio, Lexi-Comp., Inc. Last revised February 27, 2018. Accessed on June 15, 2018.
8. Palonosetron Hydrochloride Injection [Product Information]. Lake Zurich, IL. Fresenius Kabi; November 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208109s000lbl.pdf. Accessed on June 15, 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.